August 6, 2020
Study to Explore JAN101's Potential to Treat Ischemia¹ and Endothelial dysfunction² in COVID-19 patients. LAS VEGAS, Aug. 6, 2020 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, has entered into an agreement with CATO SMS, a world-leading,... READ MORE
JanOne Changes Internal Drug Candidate Name from TV1001SR to JAN101
August 4, 2020
LAS VEGAS, Aug. 4, 2020 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, announces a internal name change for its current drug candidate from TV1001SR to JAN101, soon to enter Phase 2b clinical trials as a potential... READ MORE
July 30, 2020
Houston Methodist Research Institute Professor and Chair of the Department of Cardiovascular Sciences Dr. John Cooke and LSU Health Shreveport Vice Chancellor Dr. Alan Kaye Join the JanOne Team LAS VEGAS, July 30, 2020 /PRNewswire/ -- JanOne Inc. (NASDAQ:JAN), a company focused on finding treatments for conditions that cause severe pain and bringing to market... READ MORE
July 21, 2020
IND transfer clears path for Phase 2b trials of potential Peripheral Artery Disease (PAD) treatment and opens the door to explore other vascular applications LAS VEGAS, NV, July 21, 2020 - JanOne Inc. (NASDAQ: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive pain-relieving properties,... READ MORE
July 8, 2020
LAS VEGAS, July 8, 2020 /PRNewswire/ -- JanOne Inc. (NASDAQ:JAN), a company focused on finding treatments for conditions that cause severe pain and bringing to market drugs and therapies with non-addictive pain-relieving properties, continues to broaden the medical and clinical competency of its scientific advisory board. We are proud to announce the addition of two... READ MORE
June 30, 2020
Ross to play an instrumental role in the development of the company’s strategic plans to bring non-addictive pain medications to market Las Vegas, Nevada, June 30, 2020 – JanOne Inc. (NASDAQ:JAN), a company focused on finding treatments for conditions that cause severe pain and bringing to market drugs and therapies with nonaddictive pain-relieving properties announced... READ MORE
JanOne taps distinguished chemist Dr. Doug Flanagan as chief formulation advisor
June 25, 2020
Dr. Flanagan, an accomplished chemist and formulation specialist, leads manufacturing and clinical development of JanOne’s PAD candidate TV1001SR LAS VEGAS, NV, June 25, 2020 - JanOne Inc. (NASDAQ: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive pain relieving properties, continues to build a world-class... READ MORE
JanOne Launches Strategic Alternatives Process for Legacy Businesses
June 18, 2020
LAS VEGAS, June 18, 2020 – JanOne Inc. (Nasdaq:JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive pain relieving properties, today announced the commencement of a strategic alternative process for its legacy businesses in an effort to enhance shareholder value. This review process will be... READ MORE
February 6, 2020
JanOne’s lead drug clinical candidate TV1001SR to treat PAD and associated pain will be manufactured by CoreRX Pharma with phase 2b trials expected to begin Q4 2020 LAS VEGAS, NV, February 6, 2020 - JanOne Inc. (NASDAQ: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with... READ MORE